Clinical Trial

Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated April 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
For unresectable locally-advanced non-small cell lung cancer, chemoradiotherpay plus immunotherapy is recommended by PACIFIC trial. However, it is unclear whether surgery can provide survival benefit for patients with tumors initially unresectable transformed into resectable ones after chemoimmunotherapy. This trial aims to investigate the efficacy and safety of the therapeutic regimen of chemoimmunotherapy plus surgery.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-03-10; most recent amendment 2024-09-08.
Status change: Not Yet Recruiting → Recruiting 2023-03-14
Trial Details
NCT Number NCT05766800
Lead Sponsor Shanghai Pulmonary Hospital, Shanghai, China
Conditions Locally Advanced, Non-small Cell Lung Cancer
Enrollment 100 participants
Start Date 2023-03-14
Primary Completion 2025-04-01 (estimated)
Study Completion 2027-04-01 (estimated)
Updated on ClinicalTrials.gov 2024-09-19